Adam Zamecnik

After past challenges caused by reimbursement drug price cuts imposed by the Japanese government, Chemiphar has managed to keep its operating profits in the black in the second quarter of its 2024 financial year.

Reflecting the company's acquisition of Alimera Sciences, ANI Pharmaceuticals has shared the first results that included new assets as it pushes to a more diversified business strategy.

Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.

Amphastar's leadership has discussed its strategy and latest results as part of a fireside chat at this year's Jefferies Healthcare Conference, restating its expectations of potential approvals of its GLP-1 candidate in 2025.

Hikma aims to launch fewer, but more material, products in the coming years as part of a shift in its research and development strategy that was discussed in a Q&A at this year's Jefferies Healthcare Conference.

Following its recent presentation of results for the third quarter of the 2024 fiscal year, Organon's US biosimilars lead Jon Martin spoke to Generics Bulletin about the company's adalimumab plans and strategy with upcoming launches, as well as how these will benefit from the firm's focus on women's health.

A few months after a positive Phase III trial readout, Henlius has filed an application for its Organon-partnered Perjeta biosimilar in its domestic Chinese market.

The two companies have signed a co-development agreement focused on the potential creation of new long-acting injectable therapies for psychiatric conditions for an undisclosed financial sum.

Rounding up another important year in the fight against HIV, the MPP's executive director Charles Gore speaks to Generics Bulletin about the organization's biggest milestones in the past 12 months.

Adding to five new clinical trials launched in 2024, Xentria is doubling down on its ambitions in the biosimilars arena with up to six further studies in the coming year.